# Chronic Venous Insufficiency: Pathophysiology and Classification

## Overview

Chronic venous insufficiency (CVI) refers to a range of disorders caused by prolonged venous hypertension in the lower extremities. It affects a significant portion of the population, with prevalence rates reaching 25-40% in women and 10-20% in men in Western countries. CVI contributes substantially to morbidity, disability, and healthcare expenses. The disease progresses along a continuum, beginning with telangiectasias and potentially advancing to venous ulceration, reflecting increasing severity.

## Pathophysiology

### Normal Venous Physiology

Venous return from the lower limbs relies on three interconnected venous systems: superficial, deep, and perforating veins. Bicuspid valves within these veins maintain unidirectional blood flow, directing blood from the superficial to the deep venous system and upward toward the heart. The calf muscle pump plays a critical role by generating pressures as high as 200-300 mmHg during contraction, effectively propelling blood centrally. Normally, ambulatory venous pressure decreases from approximately 80 mmHg when standing to 20-30 mmHg during walking, facilitating efficient venous return.

### Venous Valve Incompetence

Valve incompetence is a central mechanism in CVI and can be classified as primary or secondary. Primary valve failure arises from idiopathic degeneration of valve cusps and the venous wall, whereas secondary failure results from post-thrombotic damage to valve leaflets. This incompetence leads to reflux and sustained ambulatory venous hypertension. The progression of valve incompetence typically follows a distal-to-proximal pattern, known as the descending theory. Additionally, incompetence of perforator veins allows high pressures from the deep venous system to be transmitted to superficial veins and the overlying skin, exacerbating venous hypertension.

### Calf Muscle Pump Failure

Even in the presence of intact valves, failure of the calf muscle pump can contribute to venous hypertension. Factors such as ankle joint immobility, neuromuscular disorders, obesity, and sedentary lifestyle impair the pump’s function. A reduced ejection fraction of less than 40% correlates with more severe CVI. Air plethysmography is a useful tool to quantify calf muscle pump function objectively.

### Inflammatory Cascade and Tissue Damage

Venous hypertension triggers activation of endothelial cells, which upregulate adhesion molecules like ICAM-1 and VCAM-1. This promotes trapping and activation of white blood cells within capillaries, a process described by the "leukocyte trapping" hypothesis. Activated leukocytes release proteolytic enzymes, reactive oxygen species, and inflammatory mediators that damage the surrounding tissue. The formation of pericapillary fibrin cuffs impairs oxygen diffusion to tissues, known as the fibrin cuff theory. Overexpression of matrix metalloproteinases further degrades the extracellular matrix. Chronic inflammation leads to skin changes such as lipodermatosclerosis, atrophie blanche, and ultimately ulceration. Additionally, growth factors become trapped within fibrin cuffs, hindering wound healing.

<image>Diagram of the lower extremity venous system showing superficial, deep, and perforating veins with valve locations and direction of normal flow</image>

## CEAP Classification

### Clinical (C) Classification

The clinical classification of CVI ranges from C0 to C6, with additional subcategories. C0 indicates no visible or palpable signs of venous disease. C1 includes telangiectasias less than 1 mm or reticular veins measuring 1-3 mm. C2 corresponds to varicose veins larger than 3 mm in diameter, with C2r denoting recurrent varicose veins. C3 is characterized by venous edema. Skin changes are classified as C4a for pigmentation or eczema, C4b for lipodermatosclerosis or atrophie blanche, and C4c for corona phlebectatica. C5 represents a healed venous ulcer, while C6 indicates an active venous ulcer, with C6r describing recurrent active ulcers. The subscript "s" or "a" is added to denote symptomatic or asymptomatic status, respectively.

| CEAP Class | Clinical Description |
|-----------|---------------------|
| C0 | No visible or palpable signs of venous disease |
| C1 | Telangiectasias (<1 mm) or reticular veins (1–3 mm) |
| C2 | Varicose veins (>3 mm); C2r = recurrent |
| C3 | Venous edema |
| C4a | Pigmentation or eczema |
| C4b | Lipodermatosclerosis or atrophie blanche |
| C4c | Corona phlebectatica |
| C5 | Healed venous ulcer |
| C6 | Active venous ulcer; C6r = recurrent |

### Etiology (E)

Etiologic classification includes Ec for congenital causes, Ep for primary degenerative disease, Es for secondary post-thrombotic causes, and En when no venous cause is identified.

### Anatomy (A)

Anatomic classification identifies the involved venous segments: As for superficial veins, Ap for perforating veins, Ad for deep veins, and An when no venous location is identified.

### Pathophysiology (P)

Pathophysiologic classification includes Pr for reflux, Po for obstruction, Pr,o for combined reflux and obstruction, and Pn when no venous pathophysiology is identified.

<image>Clinical photographs showing the progressive stages of chronic venous insufficiency from C1 telangiectasias through C6 active venous ulceration</image>

## Venous Hemodynamic Assessment

### Duplex Ultrasonography

Duplex ultrasonography is the gold standard for both anatomic and functional evaluation of venous disease. It is performed with the patient standing and includes augmentation maneuvers such as Valsalva and calf compression/release to provoke reflux. Reflux is defined as retrograde flow lasting more than 0.5 seconds in superficial veins and more than 1.0 second in deep veins. This modality maps incompetent saphenous trunks, tributaries, perforators, and deep veins, and can identify post-thrombotic changes such as wall thickening and echogenic intraluminal material.

### Air Plethysmography (APG)

Air plethysmography provides a noninvasive quantification of venous hemodynamics by measuring venous volume, venous filling index (VFI), ejection fraction of the calf pump, and residual volume fraction. A VFI greater than 2 mL/sec indicates significant reflux. APG is particularly useful in research settings and for comprehensive hemodynamic assessment.

### Ambulatory Venous Pressure (AVP)

Ambulatory venous pressure measurement, once considered the gold standard, is an invasive technique involving dorsal foot vein cannulation. It measures the pressure drop during tiptoe exercises. An AVP exceeding 40 mmHg after exercise correlates with skin changes and ulceration, while a venous refilling time under 20 seconds indicates significant reflux. However, this method has largely been replaced by noninvasive techniques.

### Photoplethysmography (PPG)

Photoplethysmography is a noninvasive screening tool that measures venous refilling time using infrared light. A normal refilling time exceeds 20 seconds. When combined with tourniquet testing, PPG can help localize the site of reflux.

<image>Duplex ultrasound images demonstrating normal antegrade venous flow versus pathologic reflux with spectral Doppler waveforms after calf augmentation</image>

## Clinical Manifestations

### Skin Changes

Chronic venous hypertension leads to several characteristic skin changes. Hemosiderin deposition causes brown discoloration due to breakdown of extravasated red blood cells, typically seen in the medial ankle or gaiter area. Venous eczema presents as erythematous, pruritic, and sometimes weeping dermatitis, which can be mistaken for cellulitis. Lipodermatosclerosis involves fibrosis of the skin and subcutaneous tissue, producing an "inverted champagne bottle" contour of the leg. Atrophie blanche appears as white, atrophic, stellate scars surrounded by hyperpigmentation. Corona phlebectatica manifests as fan-shaped telangiectasias around the medial or lateral ankle.

### Venous Ulceration

Venous ulcers occur in approximately 1-2% of patients with CVI, with a lifetime prevalence near 1%. They are typically located at the medial malleolus within the gaiter area. These ulcers are shallow with irregular borders and are often surrounded by lipodermatosclerosis. They have a high recurrence rate, with 50-70% recurring within 1-2 years if not definitively treated. Differential diagnoses include arterial ulcers, neuropathic ulcers, malignancies, vasculitis, and pyoderma gangrenosum.

## Venous Clinical Severity Score (VCSS)

The Venous Clinical Severity Score assesses ten clinical descriptors, each scored from 0 to 3. These descriptors include pain, varicose veins, edema, skin pigmentation, inflammation, induration, number, size and duration of ulcers, and use of compression therapy. The maximum score is 30, and the VCSS is used to monitor treatment response. It is more sensitive to clinical changes than the CEAP classification. The revised VCSS (rVCSS) has been validated for both research and clinical applications.

## Management Principles

### Conservative Therapy

Compression therapy remains the cornerstone of CVI treatment. Graduated compression stockings with pressures of 20-30 or 30-40 mmHg are commonly used. Additional conservative measures include leg elevation above heart level, regular exercise, weight management, and meticulous skin care with moisturization to prevent eczema.

### Pharmacologic Agents

Several pharmacologic agents have roles in managing CVI. Micronized purified flavonoid fraction (MPFF or diosmin) reduces edema and promotes ulcer healing. Horse chestnut seed extract (aescin) decreases capillary permeability. Pentoxifylline serves as an adjunct in venous ulcer healing by reducing white blood cell activation. Sulodexide, a glycosaminoglycan, possesses antithrombotic and anti-inflammatory properties. These agents are more commonly used in Europe, with limited adoption in North America.

### Definitive Treatment

Definitive treatment targets correction of the underlying hemodynamic abnormalities. Superficial venous ablation techniques, such as endovenous laser or radiofrequency ablation, are widely employed. Perforator vein interruption can be achieved via subfascial endoscopic perforator surgery or percutaneous ablation. In cases of post-thrombotic disease, deep venous reconstruction including valve repair, transplantation, or stenting may be necessary.

<image>Air plethysmography tracing showing venous volume changes during calf pump exercises, illustrating normal versus abnormal ejection fraction and venous filling index</image>

## Clinical Pearls

Before prescribing compression therapy, it is essential to assess the ankle-brachial index (ABI), as significant peripheral arterial disease (ABI less than 0.5) contraindicates high-compression bandaging. In patients with CVI, chronic, bilateral, or recurrent "cellulitis" is often venous eczema and should be treated with emollients and compression rather than antibiotics. The severity of reflux observed on duplex ultrasonography does not always correlate with clinical severity; therefore, clinical findings must be integrated with hemodynamic data. Post-thrombotic syndrome accounts for the majority of severe CVI cases (C4 to C6), so a history of deep vein thrombosis should always be sought. Superficial venous ablation alone can heal venous ulcers in many patients who have combined superficial and deep reflux, as demonstrated by the ESCHAR trial. Lipodermatosclerosis may clinically mimic deep vein thrombosis, making duplex ultrasound essential for accurate differentiation.

## References
- Eberhardt RT, Raffetto JD. Chronic venous insufficiency. *Circulation*. 2014;130(4):333-346.
- Lurie F, et al. The 2020 update of the CEAP classification system. *J Vasc Surg Venous Lymphat Disord*. 2020;8(3):342-352.
- Bergan JJ, et al. Chronic venous disease. *N Engl J Med*. 2006;355(5):488-498.
- Gloviczki P, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the SVS and AVF. *J Vasc Surg*. 2011;53(5 Suppl):2S-48S.
- Nicolaides A, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. *Int Angiol*. 2014;33(2):87-208.